Victoria Navarro-Compán, MD

La Paz University Hospital
Madrid, Spain

I have nothing to disclose

Presentation(s):

• 0523: Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

  Sunday, November 12, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 1397: Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 2196: Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 2198: Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 237: Raising the Bar: Optimizing Outcomes With IL-23/IL-17 Inhibitors in Spondyloarthritis

  Tuesday, November 14, 2023
  6:00 PM – 8:00 PM PT

  Disclosure information not submitted.